Participated · Series D · Jun 2026

TISSIUM is a clinical and commercial-stage MedTech company founded in 2013 that develops fully biosynthetic, biomorphic, programmable elastomeric polymers for atraumatic tissue repair and tissue reconstruction. The company’s first commercial product, COAPTIUM® CONNECT, received FDA marketing authorization and TISSIUM has entered the U.S. commercial market. Its diversified pipeline includes one commercial product and six products in development across three core verticals: atraumatic sutureless nerve repair, atraumatic hernia repair, and cardiovascular sealants. TISSIUM pairs its polymer solutions with specialized delivery and activation devices designed to optimize procedure consistency and usability. The company is based in Paris and Cambridge and operates a manufacturing site in Roncq, France. Recent financing provides capital to support commercial rollout, advance multiple clinical programs and continue expanding its proprietary biomorphic polymer platform.

Led · Series B · Jun 2026

Ona Therapeutics is a spin-off from IRB Barcelona and ICREA that develops precision-engineered antibody-drug conjugates (ADCs) to target treatment-resistant cancers. The company uses a proprietary, patient-driven discovery platform to identify tumor-specific antigens and epitopes that enable efficient internalization and targeted payload delivery. Its lead clinical program is ONA-255, initially focused on breast cancer, and it is also advancing ONA-389 targeting colorectal cancer. The company integrates target validation, antibody engineering, optimized payload selection and validated linker-payload technologies in its ADC development approach. Led by CEO Valerie Vanhooren, Ona plans to use the Series B proceeds to advance clinical development of its lead and second programs. The article does not disclose revenue, user metrics or a company valuation.

Led · Series C · Apr 2025

deepull is a Barcelona, Spain-based medical diagnostics company focused on culture-free diagnostic solutions for sepsis and acute infections. It is developing the UllCORE BSI Test, an automated, walkaway system that uses molecular techniques to extract and detect microbial DNA directly from whole blood. The multiplex PCR test covers 95% of sepsis-causing pathogens, including bacteria and fungi, and detects antibiotic resistance genes, providing critical results in about one hour. deepull intends to use the €50M Series C proceeds to finalize clinical validation and expedite regulatory approval of its UllCORE diagnostic system. The company is led by CEO Jordi Carrera. The Series C included participation from multiple existing investors alongside the new lead investors. DeepUll is a medical technology company developing culture-free diagnostics for early identification of sepsis and other acute infections. Founded in 2020 in Barcelona by the founders of STAT-Dx, the company has assembled a team of globally recognized experts. Its sepsis product is designed to detect more than 250 pathogens and 15 resistance genes from 10 mL of blood in about one hour. The product also generates phenotypic antimicrobial susceptibility results in roughly eight hours without requiring a positive blood culture. Intended as a desktop, end-to-end automated device, it is designed for deployment in laboratories, emergency departments and ICUs. The company aims to improve patient outcomes and reduce unnecessary antimicrobial use; the recent Series B financing that reached €17M will support platform development and the path to market. DeepUll develops culture-free, affordable diagnostic solutions aimed at the early identification of sepsis and other acute infections. Its core product is an automated, desktop diagnostics platform designed to detect more than 250 pathogens and about 15 resistance genes in one hour from 10 mL of whole blood. The system produces phenotypic antimicrobial-susceptibility results in about eight hours without requiring a positive blood culture and is intended for deployment in laboratories, emergency rooms and ICUs. DeepUll’s platform includes end-to-end automation and leverages artificial intelligence to provide medical decision support across early recognition, precise diagnostics and therapy guidance. To accelerate development, DeepUll will expand its RD&I activities to bring the automated diagnostics device toward clinical use. The company was founded in 2020 in Barcelona by the founders of STAT-Dx. DeepUll develops culture-free diagnostic solutions for sepsis and acute infections. Its sepsis product is designed to detect more than 250 different pathogens and about 15 resistance genes in one hour starting from 10mL of whole blood. The product will generate phenotypic antimicrobial susceptibility results in about eight hours, without requiring a positive blood culture. It is planned as a desktop system with end-to-end automation, intended to be placed in any clinical setting. The company raised €13M in a Series B to progress the development of its sepsis recognition platform toward the market. DeepUll was founded by Jordi Carrera and Rafel Bru, who previously co-founded STAT-Dx (acquired by Qiagen in 2018), and is based in Barcelona, Spain. DeepUll is building a diagnostic platform that identifies pathogens and provides antibiograms in a few hours without prior culture, and incorporates patient immunological status and AI to predict sepsis onset and evolution. The system aims to enable earlier, precision therapeutic recommendations by combining pathogen detection with data-driven assessment of the patient’s immune and functional status. The company plans to validate the underlying technologies and build initial diagnostic units to demonstrate clinical utility. The funds raised in the announced round are intended to cover the financial needs for technology validation and the development of first devices. DeepUll was founded in 2019 by Jordi Carrera and Rafel Bru and is based in the Parc Científic de Barcelona. The team highlights prior entrepreneurial experience from selling STAT-Dx to QIAGEN and positions the product to address sepsis and antibiotic resistance at hospital scale.

Participated · Series B · Sep 2024

CorFlow Therapeutics is developing the CoFl system to provide timely, accurate detection of microvascular obstruction (MVO) in the cath lab immediately after stent implantation and to enable localized delivery of therapeutics to the microvasculature. The technology integrates with standard guide catheter and wire access and is intended to both diagnose MVO and deliver treatments at the point of care. CorFlow has reported recent data from over 70 patients in its first-in-human MOCA I trial and an extensive preclinical program supporting its approach. The company plans a MOCA II pivotal IDE trial in the US and Europe to validate CoFl against contrast-enhanced cardiac MRI and to support US market clearance. It will also run an adaptive platform therapy study in Europe to evaluate multiple therapeutic agents delivered via CoFl and measure clinical and imaging outcomes up to six months. Headquartered in Baar, Switzerland and founded in 2016, CorFlow is collaborating with academic partners including the University of Bern, ETH Zurich and University Hospital Zurich. CorFlow Therapeutics develops the Controlled Flow Infusion (CoFITM) system and a proprietary dynamic Microvascular Resistance (dMVRTM) concept to detect and treat microvascular obstruction (MVO) in the cathlab. The CoFITM system is positioned as a combined diagnostic and therapeutic technology that enables detection and low-flow infusion treatment of MVO immediately after reopening epicardial arteries. Seed proceeds will finance the First-in-Man MOCA I (MVO with CoFITM System Assessment) safety and feasibility trial in 40 acute heart attack patients. MOCA I will measure peri-procedural dMVR and compare those values to post-procedure contrast-enhanced MRI, and will investigate low-flow infusion of approved therapeutic agents to reduce MVO. The company cites that around 50% of acute heart attack patients develop MVO, translating to roughly 200,000 patients annually, and notes MVO is an independent predictor of heart failure and death. CorFlow has presented nonclinical data at major cardiology meetings (ACC, EuroPCR, ESC) and plans further presentation at TCT; it aims to raise a Series A in 2019 to secure longer-term R&D, clinical, and regulatory activities. CorFlow Therapeutics is developing proprietary technologies to diagnose and treat microvascular obstructions (MVO) in severe heart attack patients. Its technologies aim to enable interventional cardiologists to diagnose and treat MVO, potentially reducing short- and long-term complication rates. The company is led by CEO and co-founder Jon H. Hoem. Headquartered in Baar, Switzerland, CorFlow has raised more than CHF5M in seed funding to date. It completed a CHF 2.6M first close of a Seed+ round to advance clinical development. The company plans to use the funds to finance the 80-patient First-in-Man MOCA (MVO with CoFI™ System Assessment) clinical trial in Europe and intends the Seed+ as the basis for a larger Series A to secure long-term R&D, clinical, and regulatory activities.

Participated · Seed · Jun 2024

Biophta is a Paris-based preclinical biotech developing a thiomer biopolymers technological platform for ocular diseases. Its lead product is a 3mm ophthalmic insert that transforms on the eye into a hydrogel pellet and delivers a continuous, controlled low dose of drug for seven days. The company holds an intellectual-property position on the platform and conducted initial development with the Paris Institut de la Vision and Nancy Université de Lorraine's CITHEFOR research team. Biophta plans to use the new funding to accelerate a first-in-human trial of topical ophthalmic inserts for glaucoma and to advance a second program targeting macular edema. The €6.5M seed financing will fund those clinical and development activities. Founders Jean Cuiné and Jean Garrec together bring over 40 years of experience in ophthalmology and drug development.